Navigation Links
Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Date:7/16/2009

PITTSBURGH, July 16 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg (base).

Liothyronine Sodium Tablets are the generic version of King Pharmaceuticals' thyroid deficiency treatment Cytomel(R), which had total U.S. sales of approximately $54 million for the 12 months ending March 31 for the same strengths, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 120 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
2. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
3. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
4. Mylan Announces Successful Matrix Delisting Offer
5. Mylan Announces Change in Board Leadership
6. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
7. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan Confirms First-to-File Patent Challenge Relating to Xeloda(R) Cancer Treatment
10. Andrew G. Cuneo Joins Mylan as Vice President of Global Business Development
11. Mylan Announces Clarinex(R) Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... VA (PRWEB) , ... March ... ... Evaluation Reports: Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. ... 3:00 p.m. ET, http://www.fdanews.com/mdclineval                  , How will the new EU ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions unveils the ... 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... chart types with a comprehensive set of features including built-in workflow, interactive audit ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the true-life ... infinitely more profound faith of God’s promise of Heaven for His people. “My Journey ... each day with his wife, three children and six grandchildren living and doing for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") ... is pleased to announce that its majority-owned subsidiary, ... U.S. Food and Drug Administration (FDA) for the ... tablets in the 12.5 mg and 25 mg ... equivalent of the branded product Xenazine ® ...
(Date:3/23/2017)... , March 23, 2017 ReNeuron ... its CTX cells in chronic stroke patients, despite not meeting ... primary outcome measure, the Action Research Arm Test (ARAT). As ... to a pivotal controlled clinical study in 2017. Beyond CTX, ... (RP) trial in 2017 and Phase I data from its ...
(Date:3/23/2017)... 2017 The Board of Directors of NeuroVive ... Meeting, which is to take place on Thursday, April 27, 2017, ... Lund, Sweden . ... Please see the attached notification, which is being announced within ... NeuroVive Pharmaceutical AB (Publ) The Board Of Directors About ...
Breaking Medicine Technology: